期刊文献+

酒石酸美托洛尔联合盐酸胺碘酮片对冠心病伴心律失常患者心功能及用药不良反应的影响

Effects of metoprolol tartrate combined with amiodarone hydrochloride tablets on cardiac function and adverse drug reactions in patients with coronary heart disease complicated with arrhythmia
下载PDF
导出
摘要 目的探讨酒石酸美托洛尔联合盐酸胺碘酮片对冠心病(CHD)伴心律失常患者心功能及用药不良反应的影响。方法选择2021年1月至2022年6月收治的96例CHD伴心律失常患者作为研究对象,将其随机分为单一组和联合组,每组48例。单一组给予盐酸胺碘酮片治疗,联合组在单一组治疗基础上增加酒石酸美托洛尔治疗。比较两组的治疗效果。结果联合组的治疗总有效率显著高于单一组(P<0.05)。治疗后,联合组的左心室射血分数(LVEF)高于单一组,左心室收缩末期内径(LVESD)、左心室收缩末期容积(LVESV)及左心室舒张末期容积(LVEDV)小于单一组(P<0.05)。治疗后,联合组的QT离散度、QRS波时限变化、室性期前收缩频率、短阵室性心动过速频率显著低于单一组,窦性心博R-R间期标准差及相邻窦性心律R-R间期平均值高于单一组(P<0.05)。治疗后,联合组的B型脑钠肽(BNP)、心肌肌钙蛋白T(cTnT)、可溶性ST_(2)蛋白(sST_(2))及血乳酸(BLA)水平显著低于单一组(P<0.05)。两组治疗期间的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论酒石酸美托洛尔联合盐酸胺碘酮片治疗CHD伴心律失常患者可取得安全高效的理想效果。 Objective To investigate the effects of metoprolol tartrate combined with amiodarone hydrochloride tablets on cardiac function and adverse drug reactions in patients with coronary heart disease(CHD)complicated with arrhythmia.Methods A total of 96 CHD complicated with arrhythmia patients admitted from January 2021 to June 2022 were selected as the research objects and randomly divided into single group and combined group,with 48 cases in each group.The single group was treated with amiodarone hydrochloride tablets,and the combined group was treated with metoprolol tartrate on the basis of the single group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the combined group was significantly higher than that in the single group(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)of the combined group was higher than that of the single group,and the left ventricular end-systolic diameter(LVESD),left ventricular end-systolic volume(LVESV)and left ventricular end-diastolic volume(LVEDV)were smaller than those of the single group(P<0.05).After treatment,the QT dispersion,QRS wave time limit change,ventricular premature contraction frequency and short array ventricular tachycardia frequency in the combined group were significantly lower than those in the single group,and the standard deviation of sinus R-R interval and the average value of adjacent sinus R-R interval were higher than those in the single group(P<0.05).After treatment,the levels of brain natriuretic peptide(BNP),cardiac troponin T(cTnT),soluble ST_(2) protein(sST_(2))and blood lactate(BLA)in the combined group were significantly lower than those in the single group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Metoprolol tartrate combined with amiodarone hydrochloride tablets in the treatment of CHD complicated with arrhythmia patients can achieve safe and efficient ideal effect.
作者 郭华平 刘红岗 李莹 GUO Huaping;LIU Honggang;LI Ying(Internal Medicine Department,Baishui County Hospital,Weinan 715600;Cardiovascular Internal Medicine Department,Hancheng People's Hospital,Hancheng 715400;Cardiovascular Internal Medicine Department,Xi'an No.1 Hospital,Xi'an 710002,China)
出处 《临床医学研究与实践》 2024年第17期61-65,共5页 Clinical Research and Practice
关键词 冠心病 心律失常 盐酸胺碘酮片 酒石酸美托洛尔 coronary heart disease arrhythmia amiodarone hydrochloride tablet metoprolol tartrate
  • 相关文献

参考文献15

二级参考文献125

  • 1覃智芳.观察胺碘酮治疗冠心病室性心律失常疗效与安全性[J].心血管病防治知识(学术版),2020,10(15):32-34. 被引量:1
  • 2冯伟,黄佐贵,向小霞,刘伟,何健,邬美洪.VLP对AMI合并室性心律失常患者的预后分析[J].临床心电学杂志,2019,0(6):437-439. 被引量:4
  • 3肖日国,许晓杰.双源CT测量心周脂肪体积联合血尿酸、同型半胱氨酸监测对冠心病早期诊断的价值分析[J].中国CT和MRI杂志,2020,18(1):54-56. 被引量:13
  • 4王国敏,莫淑琴.急诊应用胺碘酮治疗冠心病快速心律失常的临床疗效[J].中国老年学杂志,2014,34(9):2539-2541. 被引量:84
  • 5蒋文平,吴宁.室上性快速心律失常治疗指南[J].中华心血管病杂志,2005,33(1):2-15. 被引量:153
  • 6无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量:2045
  • 7Zipes DP,Camm AJ,Borggrefe M,et al.American College of Cardiology/American Heart Association Task Force; Euwpean Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association and the Heart Rhythm Society.ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary:A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Eur Heart J,2006,27(17):2099-2140.
  • 8Fihn SD, Gardin JM, Abrams J, et al.2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J].Circulation, 2012,126:e354-e471.
  • 9Fihn SD, Gardin JM, Abrams J, et al.2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J].Circulation, 2012,126:3097-3137.
  • 10Task force members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology[J].Eur Heart J, 2013,34:2949-3003.

共引文献319

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部